Daily Stock Analysis, GHDX, Genomic Health Inc, priceseries

Genomic Health Inc. Daily Stock Analysis
Stock Information
Open
74.65
Close
73.80
High
75.01
Low
73.70
Previous Close
74.70
Daily Price Gain
-0.90
YTD High
86.70
YTD High Date
Feb 21, 2019
YTD Low
50.77
YTD Low Date
Jun 12, 2019
YTD Price Change
11.58
YTD Gain
18.61%
52 Week High
92.18
52 Week High Date
Nov 7, 2018
52 Week Low
50.77
52 Week Low Date
Jun 12, 2019
52 Week Price Change
20.16
52 Week Gain
37.58%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 4. 2018
34.47
May 25. 2018
37.52
15 Trading Days
8.85%
Link
LONG
May 29. 2018
38.72
Jun 27. 2018
49.52
21 Trading Days
27.89%
Link
LONG
Jul 10. 2018
51.02
Jul 27. 2018
54.59
13 Trading Days
6.99%
Link
LONG
Aug 17. 2018
54.79
Oct 2. 2018
69.02
31 Trading Days
25.97%
Link
LONG
Oct 30. 2018
67.71
Nov 14. 2018
75.19
11 Trading Days
11.05%
Link
LONG
Jan 4. 2019
66.16
Jan 28. 2019
70.79
15 Trading Days
6.99%
Link
LONG
Jan 29. 2019
72.52
Feb 21. 2019
79.42
16 Trading Days
9.52%
Link
Company Information
Stock Symbol
GHDX
Exchange
NasdaqGS
Company URL
http://www.genomichealth.com
Company Phone
650-556-9300
CEO
Kimberly J. Popovits
Headquarters
California
Business Address
301 PENOBSCOT DRIVE, REDWOOD CITY, CA 94063
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Laboratories & Research
CIK
0001131324
About

Genomic Health, Inc. engages in the development and global commercialization of genomic- based clinical laboratory services that analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. Its uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott and Steven Shak in August 2000 and is headquartered in Redwood City, CA.

Description

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype SEQ Liquid Select test, a non-invasive liquid biopsy test, which uses next-generation sequencing to identify and select actionable genomic alterations to quantify the presence and burden of cancer, as well as helps to predict the sensitivity or resistance to specific drugs for patients with certain late-stage cancers, such as lung, breast, colon, melanoma, ovarian, or gastrointestinal cancers. Its development stage pipeline products include Oncotype TRACK products for non-invasive tumor monitoring. The company offers its products through a network of distributors. Genomic Health, Inc. has a collaboration agreement with Epic Sciences, Inc. The company was founded in 2000 and is based in Redwood City, California.